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 Abstract 
Many of marketed conventional dosage forms have quick drug absorption and more dosing frequency thorugh 
skin. Hence, necessity demands for delivery systems to enhance retention of drug either on skin surface or within the 
epidermis with reduction of transdermal penetration. The microsponge-based polymeric microspheres can be used 
frequently for topical which gives another possibility to advance drug products to provide a API effectively at least dose 
and to improve stability, diminish side effects and amend drug release. Conventional marketed gel proposed to act on outer 
layers of the skin which may release API on application and produce a very much concentrated layer which may  be quickly 
absorbed. Hence the necessity subsists to exploit on quantity of period that drug which can present inside the epidermis, 
while lessening its transdermal penetration keen on the body. The concentration of the polymer required to produce 
microsponges with good physical and morphological characteristics was found to be 11.0% and 13% w/v of the internal 
phase for both the polymers. The minimum concentration of the emulsifier PVA required to produce microsponges was 
found to be 0.75% w/v. . From the results it can be concluded that the microsponges Topical Gel could sustain the drug 
release over a period of 8 hours when compared to the 96% release after 6 hrs from the pure Aceclofenac. By model fitting 
of the data obtained from the drug release profile we can conclude that drug release mechanism was Higuchi (Matrix) 
Model.  
Keywords: Aceclofenac, Solubility Enhancement, BCS-II Drugs, Bioavailability. 
1. Introduction  
Microsponge can be easily assimilated into the 
TDS which may retain dosage form on skin and has been 
used as oral delivery using bioerodible polymers 
particularly for colon precise delivery which may improve 
patient passivity due to its site specificity and extending 
dosage intermissions. Microsponge is defined as porous, 
inert units which are made up of synthetic polymers and act 
as a shield to the ensnared drug from degradation which can 
be easily entrapped in the form of creams, lotions, and 
powders. In case of Cosmetics and dermatological products, 
work only at outside of skin. The active component in 
conventional marketed dosage form may extant in a 
moderately high concentration and absorbed rapidly on 
application upon skin. MDS may proposed to permit a 
modified rate of drug release of, thus posing prospective 
lessening in the side effects and maintain the therapeutic 
effect.[1-8] 
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Ideal characteristics of materials 
 It must be immiscible or little soluble in water. 
 It must be either fully miscible or partially made 
miscible with the help of third substance.  
 It must be physically and chemically inert.  
 The structure of MS should not collapse due to any 
physical or chemical change.  
 It must be stable.[9] 
Advantages 
 It can fascinate 6 times its weight water deprived of 
drying with advanced oil control.  
 It may Improve grace and aesthetics, efficacy of 
product. 
 It permits loading of immiscible drugs.  
 It provides ER dosage and Countenances novel creation 
form which can decrease irritation, improved tolerance, 
hence extensive patients acceptance.  
 It also increases physical and chemical stability.[10-13] 
 
2. Materials and methods 
Aceclofenac was received as a gift sample from 
CAPTAB Pharma. PVT. LTD., Vadodara. Ethyl cellulose, 
Propylene Glycol, Triethanolamine, Eudragit RS 100 and 
PVA were received as a gift sample from Astron Research 
Limited, Ahmadabad. Ethanol was received as a gift sample 
from Lobachemi Private Limited, Mumbai. Liquid Paraffin 
and Petroleum Ether were received as a gift sample from 
Merck Specialties Private Limited, Mumbai. Carbopol 934 
P was received as a gift sample from Ethicare 
Pharmaceutical PVT. LTD, Por.[14-20] 
2.1 Method of Preparation Aceclofenac Microsponges 
loaded Topical Gel  
The Carbopol 934-P was accurately weighed and 
liquefied in 100 mL of water for 2 hours soaking with 600 
RPM agitation then penetration enhancer was added to the 
formulated gel which may prevent drying of gel. To this 
aqueous solution of Triethanolamine was added with slow 
agitation with continuous stirring. The Aceclofenac Loaded 
Microsponges were added in the gel.[21-29] 
2.2 Characterization of Aceclofenac Microsponges [30-
35] 
2.2.1 Percentage Yield 
It can be calculated by following formula. 
Percentage Yield= 
𝐖𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐦𝐢𝐜𝐫𝐨𝐬𝐩𝐡𝐞𝐫𝐞𝐬 𝐫𝐞𝐜𝐨𝐯𝐞𝐫𝐞𝐝
𝐖𝐞𝐢𝐠𝐡𝐭 (𝐝𝐫𝐮𝐠 + 𝐩𝐨𝐥𝐲𝐦𝐞𝐫)
X100 
2.2.2 Entrapment Efficiency 
It can be calculated by following formula. 
Drug Encapsulation  = 
Actual Drug Content 
X 100 
Theoretical Drug Content 
2.2.3 Drug Content: 
Weight accurate amount of 25 mg of 
Microsponges and mix in 25 mL methanol with shaking 
filter this solution using whattman filter paper and withdraw 
1 mL from this solution to volumetric flask with 10 ml 
dilution in volumetric flask.The quantitative determination 
of FLZ in microsponges had carried out using a linear 
model UV absorbance detector at 260 nm against blank 
(methanol). 
2.3 Mean Particle Size Analysis: 
Particle size analysis was done using Optical 
Microscope and Malvern Instrument. 
2.3.1 Topography by SEM 
Scanning electron microscopy (SEM) was used to 
illustrate ultra structure of prepared microsponges for 
morphology and surface topography.  
2.3.2 Differential Scanning Calorimetry  
Thermal analysis of Fluconazole loaded 
microsponges formulations was studied employing 
differential scanning calorimetry to find out nature and 
probable interaction concerning drug and polymers used. 
2.4 In Vitro Drug Release characterization of ACE 
Microsponges 
The dissolution test was performed using 900 mL 
of Phosphate buffer (pH 7.4) at the 37±.5 C and 150 RPM 
in USP-II apparatus dissolution apparatus. The samples 
were withdrawn at 1hr interval for 8 hrs with replacement 
of fresh medium and measured absorbance of the solution 
at λmax 275 nm using UV- Visible spectrophotometer to 
find out drug concentration.  
Kinetics of Drug Release 
The kinetic release study had performed to find 
drug release mechanism from dissolution parameter by 
using different various kinetic model equations.  
Zero Order Release Kinetics 
Qt = Q0 + K0t 
Where, 
Qt = amount of the drug dissolved in time t,  
Q0 = initial amount of drug in the solution (most of the 
times, Q0 = 0) and  
K0 = zero order release constant expressed in units of 
concentration/time. 
Plot: Cumulative amount of drug remaining vs time. 
First Order Kinetics 
Log C = Log C0 - Kt / 2.303 
Where, 
C0 = initial concentration of drug,  
K = first order rate constant, and 
t = time. 
Plot: log cumulative percentage of drug remaining vs. time. 
Higuchi Model  
Q = KH × t1/2 
Where, 
KH = Higuchi dissolution constant. 
Plot: cumulative percentage drug release vs Square root of 
time. 
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Hixson-Crowell Model  
WO
1/3 – Wt
1/3 = κ t 
Where, 
W0 = initial amount of drug in the pharmaceutical dosage 
form,  
Plot: cube root of drug percentage remaining in matrix vs 
time. 
Korsmeyer-PeppasModel  
Mt / M∞= k t
n
 
Where, 
Mt / M∞ = fraction of drug released at time t,  
k = release rate constant and  
n = release exponent.  
Plot: log cumulative percentage drug release vs log time. 
2.5 Anti fungal activity of Microspongic Gel 
In conical flask, Sabouraud’s dextrose agar 
dissolved in 100 ml water and pH adjusted to 5.6. The 
medium had been kept aside at R.T. after sterilization 
completed. Then Culture (Candida albicans) suspension 
(0.5 mL) in 0.9% w/v NaCl was introduced to above of 
medium. This 20 mL medium (20 mL) was decanted into a 
sterilized Petri dish by obtaining uniform in thickness. After 
0.1 mL solidifying sample solutions was fed into the cup by 
sterile pipette This petri dish had placed for incubation at 37 
ºC for 24 hours and zone of inhibition was found out. 
2.6 Accelerated stability studies of Microspongic Gel 
The drug or dosage form quality may affect under 
impact of by varying temperature, humidity and light with 
time which can be found out by stability testing. It can be 
carried out at 25°C ± 2°C/ 60% RH ± 5% RH and 40°C ± 
2°C/ 75% RH ± 5% RH for the selected formulation for 
three months. Samples were withdrawn on 0th, 30th, 60th 
and 90th day and were analyzed for physical appearance 
and drug content. 
 
Table 1: Formulation Design by 2
4
 Factorial Designs 
Batch Drug 
Drug: Polymer 
Ratio 
Int. Phase Vol.-
mL (X2) 
Liquid Paraffin 
(mL) 
PVA Con. 
mg (X3) 
Speed-RPM 
(X4) 
Time of stirring 
(Min) 
ACFECM1 ACF 92.3 15 50 0.75 2000 60 
ACFECM2 ACF 92.3 10 50 0.75 2000 60 
ACFECM3 ACF 90 15 50 0.75 2000 60 
ACFECM4 ACF 90 10 50 1 2000 60 
ACFECM5 ACF 92.3 15 50 1 2000 60 
ACFECM6 ACF 90 15 50 1 1500 60 
ACFECM7 ACF 92.3 15 50 1 1500 60 
ACFECM8 ACF 90 10 50 0.75 1500 60 
ACFECM9 ACF 92.3 10 50 0.75 1500 60 
ACFECM10 ACF 90 15 50 1 2000 60 
ACFECM11 ACF 90 15 50 0.75 1500 60 
ACFECM12 ACF 90 10 50 1 1500 60 
ACFECM13 ACF 92.3 10 50 1 2000 60 
ACFECM14 ACF 90 10 50 0.75 2000 60 
ACFECM15 ACF 92.3 15 50 0.75 1500 60 
ACFECM16 ACF 92.3 10 50 1 1500 60 
 
Table 2: Characterization of Batches ACFECM1- ACFECM16 
Batch No 
Yield-% (Y1) 
(Mean ± S.D.) 
(n = 3) 
E.E.-% (Y2) 
(Mean ± S.D.) 
(n = 3) 
P. Size-μm (Y3) 
(Mean ± S.D.) 
(n = 3) 
Drug Content 
(Mean ± S.D.) 
(n = 3) 
ACFERLM1 69.31± 1.32 85.41± 1.59 27.44± 2.16 88± 2.16 
ACFERLM2 61.62± 1.57 73.4± 1.08 19.72± 3.42 94± 1.67 
ACFERLM3 77.87± 1.83 87.25± 1.88 21.83± 3.88 89± 1.39 
ACFERLM4 63.26± 1.14 84.27± 1.37 23.48± 2.53 85± 1.83 
ACFERLM5 68.18± 1.36 82.3± 1.13 23.28± 4.07 89± 1.69 
ACFERLM6 58.72± 1.72 71.56± 1.67 38.19± 2.66 79± 1.15 
ACFERLM7 67.61± 1.63 82.42± 1.91 32.63± 1.17 87± 1.55 
ACFERLM8 71.42± 1.71 83.64± 1.29 31.51± 1.91 85± 1.73 
ACFERLM9 70.18± 1.48 68.82± 2.07 27.73± 3.45 87± 1.47 
ACFERLM10 60.67± 1.25 70.36± 1.34 17.68± 2.78 82± 1.33 
ACFERLM11 81.54± 1.56 90.41± 1.21 11.29± 2.36 87± 1.19 
ACFERLM12 69.32± 1.18 68.91± 1.43 27.81± 1.86 82± 1.33 
ACFERLM13 67.84± 1.28 81.84± 1.72 26.36± 3.13 89± 1.26 
ACFERLM14 69.63± 1.82 83.19± 1.53 16.48± 2.77 87± 1.62 
ACFERLM15 66.25± 1.25 75.01± 1.65 14.31± 1.88 86± 1.87 
ACFERLM16 64.49± 1.38 79.35± 1.42 29.91± 1.17 87± 1.45 
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Table 3: % Cumulative Drug Release profile of Batches ACFECM1 - ACFECM5 
Time (Hr) 
ACFECM1 
(Mean ± S.D.) 
(n = 3) 
ACFECM2 
(Mean ± S.D.) 
(n = 3) 
ACFECM3 
(Mean ± S.D.) 
(n = 3) 
ACFECM4 
(Mean ± S.D.) 
(n = 3) 
ACFECM5 
(Mean ± S.D.) 
(n = 3) 
0 0 0 0 0 0 
1 28.15± 1.76 26.12± 1.39 22.17± 1.62 22.13± 1.57 25.51± 1.71 
2 35.32± 1.35 35.42± 1.52 34.44± 1.77 34.61± 1.12 31.76± 1.24 
3 42.31± 1.11 44.33± 1.23 43.69± 1.67 46.37± 1.44 41.34± 1.65 
4 50.74± 1.68 49.82± 1.09 55.21± 1.18 54.83± 1.86 55.48± 1.53 
5 60.87± 1.91 59.74± 1.82 62.62± 1.92 60.57± 1.32 68.31± 1.27 
6 71.43± 1.73 73.01± 1.32 73.27± 1.34 73.54± 1.47 72.34± 1.39 
7 82.16± 1.25 84.16± 1.44 87.38± 1.49 82.56± 1.56 81.84± 1.12 
8 91.02± 1.41 93.54± 1.27 93.67± 1.55 89.81± 1.81 91.21± 1.36 
 
Table 4: % Cumulative Drug Release profile of Batches ACFECM6 – ACFECM11 
Time (Hr) 
ACFECM6 
(Mean ± S.D.) 
(n = 3) 
ACFECM7 
(Mean ± S.D.) 
(n = 3) 
ACFECM8 
(Mean ± S.D.) 
(n = 3) 
ACFECM9 
(Mean ± S.D.) 
(n = 3) 
ACFECM10 
(Mean ± S.D.) 
(n = 3) 
ACFECM11 
(Mean ± S.D.) 
(n = 3) 
0 0 0 0 0 0 0 
1 21.44± 1.87 23.33± 2.59 28.29± 1.25 24.24± 1.19 22.18± 2.12 24.68± 1.07 
2 35.31± 1.24 34.29± 1.81 36.12± 1.56 35.31± 1.74 34.42± 1.38 37.24± 1.29 
3 46.52± 1.59 45.03± 1.32 44.32± 1.83 45.33± 1.48 44.78± 1.54 46.48± 1.52 
4 52.24± 1.62 56.07± 1.43 59.77± 1.68 52.47± 1.65 55.22± 1.29 57.79± 1.78 
5 65.22± 1.31 61± 1.19 65.97± 1.29 60.32± 1.22 63.41± 1.71 61.89± 1.9 
6 70.57± 1.28 67.12± 1.92 74.93± 1.14 69.16± 1.09 74.27± 1.41 69.54± 1.35 
7 75.82± 1.07 77.02± 1.28 84.11± 2.07 80.22± 1.32 85.35± 1.17 84.49± 1.83 
8 83.11± 1.28 86.24± 1.16 91.21± 1.62 90.34± 1.77 85.72± 1.91 96.92± 1.48 
 
Table 5: % Cumulative Drug Release profile of Batches ACFECM12 – ACFECM16 
Time (Hr) 
ACFECM12 
(Mean ± S.D.) 
(n = 3) 
ACFECM13 
(Mean ± S.D.) 
(n = 3) 
ACFECM14 
(Mean ± S.D.) 
(n = 3) 
ACFECM15 
(Mean ± S.D.) 
(n = 3) 
ACFECM16 
(Mean ± S.D.) 
(n = 3) 
0 0 0 0 0 0 
1 26.52± 1.06 23.25± 1.12 25.18± 1.36 27.02± 1.29 22.98± 1.64 
2 38.32± 1.87 34.33± 2.37 33.14± 1.67 38.46± 1.16 38.04± 1.39 
3 46.56± 1.34 42.78± 1.72 42.36± 1.53 43.31± 1.91 47.37± 1.66 
4 57.24± 1.79 53.32± 1.45 56.78± 1.39 51.79± 1.36 54.13± 1.89 
5 64.29± 1.56 62.42± 1.37 60.89± 1.78 61.84± 1.16 60.19± 1.27 
6 75.59± 1.45 74.52± 1.88 70.51± 1.27 72.43± 1.47 67.11± 1.72 
7 85.82± 1.73 82.42± 1.09 82.49± 1.08 81.15± 1.68 79.31± 2.05 
8 90.83± 1.23 89.62± 1.66 90.54± 1.85 92.55± 1.08 89.11± 1.25 
Release Kinetic 
Table 6: Release Kinetic of Batches ACFECM1 - ACFECM8 
Model Parameter 
ACFEC
M1 
ACFEC
M2 
ACFEC
M3 
ACFEC
M4 
ACFEC
M5 
ACFEC
M6 
ACFEC
M7 
ACFEC
M8 
Zero 
Order 
R2 0.9325 0.9135 0.9818 0.9311 0.8921 0.9218 0.8149 0.91515 
Slope 8.825 9.22 -8.35 8.943 8.39 -8.35 8.39 9.22 
Intercept 14.14 15.67 15.54 13.69 15.61 15.54 15.61 15.67 
First 
Order 
R2 0.9743 0.9917 0.9937 0.9114 0.9809 0.9688 0.9893 0.9713 
Slope -0.2035 -0.182 -0.1645 -0.162 -0.1845 -0.1878 -0.1638 -0.2035 
Intercept 4.53 4.53 4.49 4.51 4.54 4.52 4.48 4.53 
Higuchi 
Model 
R2 0.9918 0.9944 0.9918 0.9984 0.9978 0.9982 0.9954 0.9984 
Slope 27.85 29.33 26.79 27.04 28.17 28.25 27.04 29.33 
Intercept 1.11 0.62 0.31 0.27 1.07 0.12 0.27 0.52 
Hixon 
Crowell 
R2 0.8786 0.868 0.8702 0.8589 0.8242 0.86 0.8689 0.878 
Slope 0.94 0.94 0.9 0.86 0.92 0.88 0.86 0.94 
Intercept 2.97 3.12 3.07 3.11 2.96 3.18 3.11 3.12 
Corsmeye
r Peppas 
R2 0.4828 0.5073 0.4641 0.4795 0.4444 0.4499 0.4444 0.5073 
Slope 0.56 0.56 0.56 0.53 0.54 0.53 0.54 0.57 
Intercept -0.59 -0.56 -0.58 -0.6 -0.59 -0.56 -0.59 -0.56 
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Table 7: Release Kinetic of Batches ACFECM9 – ACFECM16 
Model Parameter 
ACFEC
M9 
ACFEC
M10 
ACFEC
M11 
ACFEC
M12 
ACFEC
M13 
ACFEC
M14 
ACFEC
M15 
ACFEC
M16 
Zero 
Order 
R2 0.91689 0.9239 0.9273 0.9374 0.9345 0.9341 0.9264 0.9253 
Slope 8.883 8.883 8.496 8.421 8.825 8.943 8.421 8.496 
Intercept 14.45 14.45 13.27 12.89 14.14 13.69 12.89 13.27 
First 
Order 
R2 0.9957 0.9778 0.9893 0.9717 0.9907 0.9909 0.9747 0.9904 
Slope -0.1645 -0.1878 -0.1638 0.158 -0.182 -0.1845 0.158 -0.162 
Intercept 4.49 4.52 4.48 4.5 4.53 4.54 4.5 4.51 
Higuchi 
Model 
R2 0.9988 0.9995 0.9924 0.9913 0.9948 0.9966 0.9913 0.9914 
Slope 26.79 28.25 26.82 26.61 27.85 28.17 26.61 26.82 
Intercept 0.41 0.23 1.34 1.73 2.11 1.27 1.93 1.44 
Hixon 
Crowell 
R2 0.8712 0.86 0.8886 0.8647 0.8729 0.8842 0.8647 0.8729 
Slope 0.9 0.88 0.94 0.85 0.88 0.92 0.85 0.88 
Intercept 3.07 3.18 2.97 2.97 2.96 2.96 2.97 2.96 
Corsmeyer 
Peppas 
R2 0.4631 0.4889 0.4277 0.4664 0.4828 0.4795 0.4114 0.4438 
Slope 0.54 0.53 0.56 0.57 0.56 0.59 0.55 0.57 
Intercept -0.58 -0.56 -0.67 -0.62 -0.59 -0.6 -0.62 -0.67 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 1: Response Surface Plot: 
(a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase Concentration and Drug 
Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: Polymer Ratio on 
% yield (Y1) 
Design-Expert® Software
Factor Coding: Actual
Yield (%)
84
58
X1 = A: Drug: Polymer Ratio
X2 = B: Volume of Internal Phase
Actual Factors
C: PVA concentration = 0.875
D: Speed = 1750
90 90.46 90.92 91.38 91.84 92.3
10
11
12
13
14
15
Yield (%)
A: Drug: Polymer Ratio (mg)
B
:
 
V
o
l
u
m
e
 
o
f
 
I
n
t
e
r
n
a
l
 
P
h
a
s
e
 
(
m
L
)
66
68
70
72
74
76
Design-Expert® Software
Factor Coding: Actual
Yield (%)
84
58
X1 = B: Volume of Internal Phase
X2 = A: Drug: Polymer Ratio
Actual Factors
C: PVA concentration = 0.875
D: Speed = 1750
10 11 12 13 14 15
90
90.46
90.92
91.38
91.84
92.3
Yield (%)
B: Volume of Internal Phase (mL)
A
:
 
D
r
u
g
:
 
P
o
l
y
m
e
r
 
R
a
t
i
o
 
(
m
g
)
66
68
70
72
74
76
Design-Expert® Software
Factor Coding: Actual
Yield (%)
84
58
X1 = C: PVA concentration
X2 = A: Drug: Polymer Ratio
Actual Factors
B: Volume of Internal Phase = 12.5
D: Speed = 1750
0.75 0.8 0.85 0.9 0.95 1
90
90.46
90.92
91.38
91.84
92.3
Yield (%)
C: PVA concentration (mg)
A
:
 
D
r
u
g
:
 
P
o
l
y
m
e
r
 
R
a
t
i
o
 
(
m
g
)
66
68
70
72
74
Design-Expert® Software
Factor Coding: Actual
Yield (%)
84
58
X1 = D: Speed
X2 = A: Drug: Polymer Ratio
Actual Factors
B: Volume of Internal Phase = 12.5
C: PVA concentration = 0.875
1500 1600 1700 1800 1900 2000
90
90.46
90.92
91.38
91.84
92.3
Yield (%)
D: Speed (RPM)
A
:
 
D
r
u
g
:
 
P
o
l
y
m
e
r
 
R
a
t
i
o
 
(
m
g
)
68
70
72
74
Urvashi B. Patel et al / Formulation and Development of Aceclofenac Loaded Microsponges for Topical Delivery                                  22 
IJAP (2018) 07 (04)                                                                                                                                          www.ssjournals.com 
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(d) 
Figure 2: 3D Surface Plot: (a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % yield (Y1) 
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(c) 
 
(d) 
Figure 3: Response Surface Plot: 
(a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase Concentration and Drug 
Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: Polymer Ratio on 
% E.E. (Y2) 
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Figure 4: 3D Surface Plot: (a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % E.E. (Y2) 
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(d) 
Figure 5: Response Surface Plot: Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % P.S. (Y3) 
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(d) 
Figure 6: 3D Surface Plot: (a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % P.S. (Y3) 
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Figure 7: Response Surface Plot: (a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % CDR (Y4) 
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Figure 8: 3D Surface Plot: (a) Drug Polymer Ratio and Internal Phase Concentration, (b) Internal Phase 
Concentration and Drug Polymer Ratio, (c) PVA concentration and Drug Polymer Ratio and (d) Speed and Drug: 
Polymer Ratio on % CDR (Y4) 
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Figure 9: Overlay Plot 
 
Table 8: Validation of Batches AEMS1 & AEMS2: Predicted Response 
Batch 
No 
Drug Con.-
mg (X1) 
Int. Phase Vol.-
mL (X2) 
PVA Con.-
mg (X3) 
Speed-RPM 
(X4) 
Yield-% 
(Y1) 
E.E.-% 
(Y2) 
P. Size-μm 
(Y3) 
CDR T8-% 
(Y4) 
AEMS1 92.23 10.16 0.5 1982.52 73.96 95.98 13.97 94.34 
AEMS2 92.3 10 0.5 2000 74.87 86.56 12.93 94.87 
 
Table 9: Validation Batches AEMS1 & AEMS2: Actual Response 
Batch 
No 
Drug Con.-
mg (X1) 
Int. Phase Vol.-
mL (X2) 
PVA Con.-
mg (X3) 
Speed-RPM 
(X4) 
Yield-% 
(Y1) 
E.E.-% 
(Y2) 
P. Size-μm 
(Y3) 
CDR T8-% 
(Y4) 
AEMS1 92.23 10.16 0.5 1980 72.28 93.88 14.07 93.25 
AEMS2 92.3 10 0.5 2000 73.75 87.96 11.93 91.07 
 
Table 10: % Cumulative Drug Release profile ACF Microsponge (AEMS1 and AEMS2) 
Time (hr) 
AEMS1 
(Mean ± S.D.) 
(n = 3) 
AEMS2 
(Mean ± S.D.) 
(n = 3) 
0 0 0 
1 28.12± 1.87 27.89± 1.07 
2 37.67± 1.02 39.63± 1.24 
3 48.01± 1.55 48.99± 1.39 
4 57.27± 1.72 57.12± 1.18 
5 69.9± 1.91 69.41± 1.61 
6 77.44± 1.49 78.89± 1.42 
7 86.14± 1.23 84.44± 1.26 
8 93.25± 1.65 91.07± 1.79 
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3. Result 
A topical polymeric microsponges formulation of 
Aceclofenac was formulated using Ethyl cellulose and 
Eudragit ES100.  The internal phase suitable for the 
preparation of microsponges was found to be Acetone and 
the external phase was found to be Liquid Paraffin by 
solubility analysis of drug and polymer. The concentration 
of the polymer required to produce microsponges with good 
physical and morphological characteristics was found to be 
11.0% and 13% w/v of the internal phase for both the 
polymers. The volume of internal and external phase 
required to prepare good microsponges was found to be 
20mL of internal and 50mL of the external phase. 
The minimum concentration of the emulsifier PVA 
required to produce microsponges was found to be 0.75% 
w/v. The minimum speed and time of stirring was found to 
be 2000rpm for 90 Min. The ratio of drug: polymer 
required to produce microsponges with good encapsulation 
efficiency was found to be from 7:1 to 13:1. Below this 
ratio, the microsponges formed had low capacity 
encapsulation of the drug and above this range there was no 
further increase in the encapsulation efficiency. Hence, it 
was concluded that 11: 1 to 13: 1 were optimum ratios of 
drug: polymer to produce good microsponges. To begin 
with, the variables involved (viz. Selection of internal and 
external phase, selection of the type and concentration of 
emulsifier, selection of speed and time of stirring required 
for preparation) in the preparation of the microsponges 
were identified CQAs and their effect on the physical and 
morphological properties of the microsponges was to 
develop a QbD approach. In factorial design, the amount of 
drug (ACF): polymer (EC) ratio (X1), amount of PVA 
Concentration (X2), Internal Phase Concentration (X3) and 
Speed (X4) were taken as independent variables while % 
Yield (Y1), % E. E (Y2). Particle sizes (Y3), % CDR (Y4) 
were selected as dependent variables for both factorial 
designs. The microsponges after check point analysis which 
gave better physical, morphological and % encapsulation in 
either of the polymers were selected for incorporation into 
the gel formulations. The release profile of the Aceclofenac 
in the form of microsponges loaded Topical Gel was 
compared with that of the pure Aceclofenac Topical Gel. 
From the results it can be concluded that the microsponges 
Topical Gel could sustain the drug release over a period of 
8 hours when compared to the 96% release after 6 hrs from 
the pure Aceclofenac. By model fitting of the data obtained 
from the drug release profile we can conclude that drug 
release mechanism was Higuchi (Matrix) Model. The 
formulations Optimized Aceclofenac Microsponges 
(AERMS2) loaded Gel was subjected to stability studies for 
3 months and significant changes observed.  
4. Conclusion 
From the study it can be concluded that it is 
possible to design a topical polymeric microsponges 
formulation for anti fungal drug Fluconazole and 
Aceclofenac may increase efficacy and patient compliance 
which are of prime importance. However, in – vivo 
experiments are essential to establish the actual usefulness 
of these microsponges. 
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